Global Alpha Capital Management Ltd. Acquires 88,100 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Global Alpha Capital Management Ltd. raised its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 16.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 624,550 shares of the specialty pharmaceutical company’s stock after buying an additional 88,100 shares during the period. ANI Pharmaceuticals accounts for approximately 2.5% of Global Alpha Capital Management Ltd.’s portfolio, making the stock its 16th biggest holding. Global Alpha Capital Management Ltd.’s holdings in ANI Pharmaceuticals were worth $34,525,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. US Bancorp DE increased its holdings in shares of ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after acquiring an additional 531 shares during the last quarter. KBC Group NV boosted its position in ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares during the last quarter. HighTower Advisors LLC bought a new position in shares of ANI Pharmaceuticals in the third quarter valued at approximately $222,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of ANI Pharmaceuticals by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock worth $246,000 after buying an additional 412 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the transaction, the senior vice president now directly owns 49,059 shares in the company, valued at approximately $2,943,540. This represents a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the sale, the chief financial officer now owns 154,468 shares in the company, valued at $8,617,769.72. This represents a 4.63 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,300 shares of company stock worth $584,009. 12.70% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Stock Down 0.7 %

ANIP stock opened at $60.62 on Friday. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The company has a market cap of $1.27 billion, a PE ratio of -110.22 and a beta of 0.63. The business’s 50-day simple moving average is $57.64 and its 200 day simple moving average is $58.13.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price on the stock. StockNews.com cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 3rd. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. HC Wainwright restated a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, March 3rd. Finally, Guggenheim lifted their price target on ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.